Former President Donald Trump has warned that European price controls on medicines are forcing American consumers to shoulder the cost of pharmaceutical innovation. The claim, echoed in a recent op‑ed, argues that while U.S. taxpayers fund much of the research, European nations like Germany suppress prices once drugs hit the market, creating a free‑ride situation that inflates U.S. prices.

Trump’s 2022 Drug‑Pricing Executive Order Aims to Save $529 Billion

According to the White House economists cited in the article, a 2022 executive order on drug pricing and negotiations could save the United States $529 billion over ten years. The order targets the high prices Americans pay for existing medicines, which the op‑ed claims cross‑subsidize global innovation. Trump’s administration, the source notes, has used this framework to argue for a more equitable distribution of research costs.

Germany’s 2026 Legislation Would Slash Prices Further

The source reports that Germany is proposing legislation to lower prices for cutting‑edge medicines, a move that would deepen the perceived inequity. While the United Kingdom has agreed to pay 25 % more for innovative drugs in exchange for tariff relief, Germany’s strategy is to reduce prices even further, according to the op‑ed. This divergence highlights the tension between European cost‑control measures and U.S. calls for shared investment.

Defense Spending Lessons Mirror Healthcare Imbalance

Trump’s earlier criticism of NATO’s defense‑spending imbalance—where the United States bore a disproportionate share—parallels the current healthcare argument. The article notes that by 2026, Germany and other allies increased defense spending, acknowledging Trump’s stance. The same logic, the source argues, should apply to pharmaceutical innovation, with Europe contributing more to the research pipeline.

Unanswered Question: Will European Allies Shift Their Funding Models?

The op‑ed leaves open whether European nations will alter their pricing and funding strategies. It is unclear if Germany’s proposed price‑cutting legislation will be overridden by broader EU policy or if the United Kingdom’s tariff‑relief deal signals a new model. The source does not indicate whether any European government has committed to matching U.S. research subsidies.

Implications for U.S. Manufacturing and Healthcare Costs

According to the article, the U.S. is already reevaluating trade, defense , manufacturing, energy, and healthcare through the lens of euqitable contribution. A Section 301 investigation into foreign trade practices is suggested to expand to cover European pharmaceutical free‑riding, which the op‑ed claims undermines American manufacturing and raises healthcare costs. The broader impact could reshape U.S. pharmaceutical policy and international cooperation.